Genmab A/S (OTCMKTS:GNMSF) Posts Earnings Results, Beats Expectations By $5.24 EPS

Genmab A/S (OTCMKTS:GNMSF) announced its earnings results on Wednesday. The company reported $5.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $5.24, Zacks reports. Genmab A/S had a net margin of 23.49% and a return on equity of 17.73%.

Genmab A/S Trading Up 8.2 %

Shares of GNMSF stock traded up $15.78 on Friday, hitting $207.62. 30 shares of the stock were exchanged, compared to its average volume of 6,895. The firm has a market capitalization of $13.72 billion, a P/E ratio of 19.96 and a beta of 1.04. Genmab A/S has a fifty-two week low of $186.61 and a fifty-two week high of $323.02. The business has a 50-day moving average of $206.28 and a 200 day moving average of $230.43.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.